

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on Temporarily Idle Proceeds To Be Deposited as Call Deposits and in Other Forms” (《上海君實生物醫藥科技股份有限公司關於將暫時閒置募集資金以通知存款等方式存放的公告》) published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, PRC, 8 December 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun and Dr. Wang Gang as executive Directors; Dr. Feng Hui, Mr. Tang Yi and Dr. Li Xin as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purposes only*

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on Temporarily Idle Proceeds To Be
Deposited as Call Deposits and in Other Forms

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading statement or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important notice:

- Shanghai Junshi Biosciences Co., Ltd.* (the “Company”) proposes to deposit temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits, provided that it does not affect the normal progress of the Company’s investment plans funded with proceeds raised.
- As of 30 June 2023, proceeds from the initial public offering of A shares (“IPO proceeds”) had all been used according to committed investment projects (excluding surplus proceeds). It has been intended for the proceeds from the issuance of A shares to target subscribers in 2022 (“refinancing proceeds”) to be invested in the research and development projects of innovative drugs and the Junshi Biotech Scientific Headquarters and R&D Base Project, and the estimated implementation periods shall be three years. At present, among the research and development projects of innovative drugs, the Phase III international multi-center clinical study of JS001 combined with standard chemotherapy versus placebo combined with standard chemotherapy in the postoperative adjuvant therapy of gastric or gastroesophageal junction adenocarcinoma is enrolling patients. Phase III international multi-center clinical study of JS001 combined with lenvatinib and standard chemotherapy versus standard chemotherapy in the first-line treatment of

unresectable advanced intrahepatic cholangiocarcinoma has completed the enrollment of first patient in June 2023. Other clinical research and development projects and preclinical research and development projects are progressing normally. The remaining proceeds will be used in a reasonable and timely manner according to the overall progress of the investment projects. Depositing temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits will not affect the construction of the investment projects.

I. Overview of the Proceeds

In accordance with the “Approval Regarding the Registration of Shares Issued by Shanghai Junshi Biosciences Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2022] No. 2616)” (《關於同意上海君實生物醫藥科技股份有限公司向特定對象發行股票註冊的批復》(證監許可(2022)2616號)) issued by the China Securities Regulatory Commission, the Company was approved to issue 70,000,000 RMB-denominated ordinary shares to target subscribers at an issue price of RMB53.95 per share, with the total proceeds amounting to RMB3,776,500,000. Net proceeds after deducting issuance expenses (excluding tax) amounted to RMB3,744,802,800. The above funds have become fully available on 23 November 2022. RSM China (容誠會計師事務所(特殊普通合伙)) has verified the availability of the proceeds from the issuance of shares to target subscribers and issued the “Capital Verification Report” (Rong Cheng Yan Zi [2022] No. 230Z0337 (容誠驗字[2022] 230Z0337號《驗資報告》)) on 24 November 2022.

In order to regulate the management and use of proceeds of the Company and to safeguard the interests of investors, the Company established a special account for such proceeds. Upon receipt, all proceeds were deposited into the special account established by the Company, and a Tripartite Agreement on Supervision of Proceeds*(《募集資金專戶存儲三方監管協議》) was entered into by the Company, the Sponsor Institution, and the commercial bank in which the proceeds were deposited. The Company has also signed the Quadripartite Agreement on Supervision of Special Deposit Accounts for

Proceeds* (《募集資金專戶存儲四方監管協議》) with the subsidiaries implementing the investment projects, the sponsor institution and the commercial bank where the proceeds are deposited.

II. Situations Relevant to the Temporarily Idle Proceeds To Be Deposited as Call Deposits and in Other Forms

(I) Purpose

The purpose of the investment is to improve the efficiency of the use of the proceeds, to make reasonable use of part of the temporarily idle proceeds, and to increase the capital return for the Company and its shareholders under the condition that the construction and use of the investment projects funded by the proceeds will not be affected, the safety of the proceeds can be ensured and there will be no disguised change in the use of the proceeds.

(II) Types of Product

In accordance with the relevant regulations, the Company will strictly control risks and proposes to deposit part of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits, and such products shall not be used for pledge or investment for the purpose of securities investment.

(III) Validity Period of the Resolution

Valid for 12 months from the date of consideration and approval by the board of directors of the Company.

(IV) Funding sources, Investment Amount and Term

The Company proposes to deposit part of the temporary idle proceeds not exceeding RMB3.3 billion (inclusive) in the forms of call deposits, large-denomination certificates of deposit and structured deposits. Based on the use of the proceeds and the Company's operating conditions, the temporarily idle proceeds will be invested in the aforesaid products in several tranches for different terms, with the maximum period not exceeding 12 months. Within the aforesaid amount and term, the Company could use the temporarily idle proceeds on a revolving basis.

(V) Implementation Method

Within the aforesaid amount and term, the board of directors of the Company

delegates to the Chairman of the Company the authority to make investment decisions and sign relevant legal documents. The finance department of the Company shall be responsible for the organization and implementation of specific matters.

(VI) Information Disclosure

The Company will comply with its information disclosure obligations in a timely manner in accordance with the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange; and will not change the use of the proceeds in a disguised manner.

(VII) Allocation of Income

The Company's income from deposit of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits will be prioritized to make up for the shortfall in the investment amount of investment projects funded by the proceeds and the working capital required for the Company's daily operation. The Company will manage and use the proceeds in strict compliance with the requirements of regulatory measures of China Securities Regulatory Commission and the Shanghai Stock Exchange on fund-raising, and will return the funds back to the special account for proceeds upon the expiration of the call deposits, large-denomination certificates of deposit and structured deposits.

III. Impact on Daily Operation of the Company

The proposed deposit of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits by the Company is implemented on the premise of ensuring the funds required for the Company's investment projects funded by the proceeds and the safety of the proceeds, which will neither affect its normal turnover of daily funds and normal progress of the investment projects funded by the proceeds, nor the normal development of the Company's main business.

As of 30 June 2023, the IPO proceeds had all been used according to committed investment projects (excluding surplus proceeds). It has been intended for the refinancing proceeds to be invested in the research and development projects of innovative drugs and the Junshi Biotech Scientific Headquarters and R&D Base Project,

the estimated implementation periods shall be three years. Among the research and development projects of innovative drugs, the Phase III international multi-center clinical study of JS001 combined with standard chemotherapy versus placebo combined with standard chemotherapy in the postoperative adjuvant therapy of gastric or gastroesophageal junction adenocarcinoma is currently enrolling patients. Phase III international multi-center clinical study of JS001 combined with lenvatinib and standard chemotherapy versus standard chemotherapy in the first-line treatment of unresectable advanced intrahepatic cholangiocarcinoma has completed the enrollment of first patient in June 2023. Other clinical research and development projects and preclinical research and development projects progressing normally. The remaining proceeds will be used in a reasonable and timely manner according to the overall progress of the investment projects, and will not affect the construction of the investment projects.

Meanwhile, the timely deposit of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits enables the achievement of a certain amount of investment income, which is conducive to further improving the overall performance of the Company and seeking better return on investment for the Company and its shareholders.

IV. Investment Risk and Risk Control Measures

(I) Investment Risks

Although the Company intends to select call deposits, large-denomination certificates of deposit and structured deposits products which are low-risk investment products, the financial market is highly susceptible to the macro-economy. Therefore, the Company will intervene to such extent as and when appropriate, taking account of the economic situation and changes in financial market. However, the possibility that such investment may be affected by market fluctuation cannot be ruled out.

(II) Risk Control Measures

1. The board of directors of the Company authorizes the chairman of the Board to exercise the decision-making rights and execute relevant contractual documents in relation to the investment, including but not limited to selecting high-quality

cooperative banks, specifying the amount and term, choosing the categories of products, and executing contracts and agreements. The financial department of the Company is responsible for the organization and implementation of specific matters, and will analyze and monitor the investment and project progress of bank in a timely manner. Once adverse factors are identified or judged, corresponding preservation measures will be taken in time to control investment risks.

2. The internal audit department of the Company is responsible for reviewing the approval, actual operation, capital utilization and the profits and losses in relation to the purchase of call deposits, large-denomination certificates of deposit and structured deposits, urging the finance department to deal with relevant accounts in a timely manner and conducting verification on the accounting treatment. It conducts a comprehensive inspection on all the call deposits, large-denomination certificates of deposit and structured deposits of banks at the end of each quarter and reports to the audit committee on the reasonable expectation of potential gains and losses of each investment on a prudent basis.

3. The independent non-executive directors and the board of supervisors shall supervise and inspect the capital utilization and may engage professional institutions for audit when necessary.

4. The Company must conduct the relevant business in strict compliance with the relevant regulations, such as the “Regulatory Guidance for Listed Companies No.2-Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies” (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the “Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation” (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) and the Management Policies for Proceeds Raised of the Company.

V. Review Procedures

On 6 December 2023, relevant resolution was considered and approved at the twenty-fifth meeting of the third session of the board of directors and the twentieth meeting of the third session of the board of supervisors of the Company, under which

consent was given to deposit part of temporarily idle proceeds not exceeding RMB3.3 billion (inclusive) in the forms of call deposits, large-denomination certificates of deposit and structured deposits, provided that it does not affect the normal progress of the Company's investment plans funded with the proceeds raised, which is valid for 12 months from the date of consideration and approval by the board of directors. Within the aforesaid amount and term, the Company could use the proceeds on revolving basis. The independent non-executive directors of the Company have expressed their clear and independent opinion of consent on such matters. Pursuant to the relevant stipulations including the "Regulatory Guidance for Listed Companies No.2-Regulatory Requirements for the Administration and Use of Proceeds of the Listed Companies" (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the "Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation" (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》), the "Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*" (《上海君實生物醫藥科技股份有限公司章程》) and the "Management Policies for Proceeds Raised of Shanghai Junshi Biosciences Co., Ltd.*" (《上海君實生物醫藥科技份有限公司募集資金管理制度》), such matter is not subject to the consideration at the general meeting.

VI. Special Opinions

(I) Opinions of Independent Non-executive Directors

The independent non-executive directors of the Company are of the opinion that, provided that the Company's investment plans funded with proceeds raised progress normally, the Company deposits part of temporarily idle proceeds not exceeding RMB3.3 billion (inclusive) in the forms of call deposits, large-denomination certificates of deposit and structured deposits is conducive to improving the efficiency of and gains from use of proceeds, and is in the interest of the Company and its shareholders as a whole. The related contents and procedures are in compliance with the laws, regulations and regulatory documents including the "Regulatory Guidance for Listed Companies No.2- Regulatory Requirements for the Administration and Use of Proceeds of the

Listed Companies” (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the “Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation” (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) as well as the requirements under the “Management Policies for Proceeds Raised of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司募集資金管理制度》). The Company’s present deposit of part of the temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits does not conflict with the implementation plan of investment projects funded with raised proceeds and will not affect the normal progress of the investment projects funded with proceeds raised, and there is no circumstance where it will change the target use of proceeds in effect or become detrimental to the interests of the shareholders of the Company.

In summary, the independent non-executive directors of the Company agree to deposit part of temporarily idle proceeds not exceeding RMB3.3 billion (inclusive) in the forms of call deposits, large-denomination certificates of deposit and structured deposits provided that it does not affect the normal progress of the Company’s investment plans funded with proceeds raised, which shall be valid for 12 months from the date of consideration and approval by the board of directors. Within the aforesaid amount and term, the Company could use it on a revolving basis.

(II) Opinions of the Board of Supervisors

The board of supervisors of the Company is of the opinion that provided that the Company’s investment plans funded with proceeds raised progress normally, the Company deposits part of temporarily idle proceeds not exceeding RMB3.3 billion (inclusive) in the forms of call deposits, large-denomination certificates of deposit and structured deposits is conducive to improving the efficiency of and gains from use of proceeds, and is in the interest of the Company and its shareholders as a whole. The related contents and procedures are in compliance with the laws, regulations and regulatory documents including the “Regulatory Guidance for Listed Companies No. 2- Regulatory Requirements for the Administration and Use of Proceeds of the Listed

Companies” (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the “Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation” (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) as well as the requirements under the “Management Policies for Proceeds Raised of Shanghai Junshi Biosciences Co., Ltd.*” (《上海君實生物醫藥科技股份有限公司募集資金管理制度》). The Company’s present deposit of part of the temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits does not conflict with the implementation plan of investment projects funded with proceeds raised and will not affect the normal progress of the investment projects funded with proceeds raised, and there is no circumstance where it will change the target use of proceeds in effect or become detrimental to the interests of the shareholders of the Company.

Therefore, the board of supervisors of the Company agree to deposits part of temporarily idle proceeds not exceeding RMB3.3 billion (inclusive) in the forms of call deposits, large-denomination certificates of deposit and structured deposits.

(III) Verification opinion of the Sponsor Institution

Upon verification, Haitong Securities Co., Ltd., the Sponsor Institution of the Company, is of the view that:

The proposal of deposit of part of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits by the Company has been approved by the Company’s board of directors and board of supervisors. The independent directors have issued explicit consent and completed the required procedure for approval. The Company may improve the efficiency of the use of proceeds by depositing part of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits. There is no circumstance where such proposal will change the use of proceeds in effect and affect the normal progress of the investment projects. The proposal is in compliance with the relevant requirements of the “Regulatory Guidance for Listed Companies No.2-Regulatory Requirements for the Administration and Use of Proceeds of the Listed

Companies” (《上市公司監管指引第2號—上市公司募集資金管理和使用的監管要求》), the “Rules Governing the Listing of Securities on the STAR Market of the Shanghai Stock Exchange” (《上海證券交易所科創板股票上市規則》), “Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation” (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》) and the Management Policies for Proceeds Raised of the Company (《上海君實生物醫藥科技股份有限公司募集資金管理制度》). The Sponsor Institution has no objection to the proposal of deposit of part of temporarily idle proceeds in the forms of call deposits, large-denomination certificates of deposit and structured deposits by the Company.

VII. Attachments to the Online Announcement

(I) Independent Opinion of Independent Non-executive Directors on the Relevant Matters at the Twenty-fifth Meeting of the Third Session of the Board of Directors of Shanghai Junshi Biosciences Co., Ltd.*;

(II) “Verification Opinion of Haitong Securities Co., Ltd. on Temporarily Idle Proceeds To Be Deposited as Call Deposits and in Other Forms by Shanghai Junshi Biosciences Co., Ltd.*” issued by the Sponsor Institution, Haitong Securities Co., Ltd. (《海通證券股份有限公司關於上海君實生物醫藥科技股份有限公司將暫時閒置募集資金以通知存款等方式存放的核查意見》).

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

9 December 2023

** For identification purpose only*